CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
CRISPR Therapeutics (Nasdaq: CRSP) has announced its participation in the upcoming Jefferies London Healthcare Conference. CEO and Chairman Samarth Kulkarni, Ph.D., will deliver a presentation on Wednesday, November 20, 2024, at 4:00 p.m. GMT. The presentation will be accessible through a live webcast on the company's website under the 'Events & Presentations' section, with a replay available for 14 days afterward. CRISPR Therapeutics specializes in developing transformative gene-based medicines for serious diseases.
CRISPR Therapeutics (Nasdaq: CRSP) ha annunciato la sua partecipazione al prossimo Jefferies London Healthcare Conference. Il CEO e Presidente Samarth Kulkarni, Ph.D., terrà una presentazione mercoledì 20 novembre 2024, alle 16:00 GMT. La presentazione sarà accessibile tramite un webcast dal vivo sul sito web dell'azienda nella sezione 'Eventi e Presentazioni', con una registrazione disponibile per 14 giorni dopo. CRISPR Therapeutics si specializza nello sviluppo di farmaci a base genomica per malattie gravi.
CRISPR Therapeutics (Nasdaq: CRSP) ha anunciado su participación en la próxima Jefferies London Healthcare Conference. El CEO y presidente Samarth Kulkarni, Ph.D., realizará una presentación el miércoles 20 de noviembre de 2024, a las 4:00 p.m. GMT. La presentación estará disponible a través de una transmisión en vivo en el sitio web de la compañía en la sección 'Eventos y Presentaciones', con una repetición disponible durante 14 días después. CRISPR Therapeutics se especializa en el desarrollo de medicamentos basados en genes para enfermedades graves.
CRISPR Therapeutics (Nasdaq: CRSP)는 다가오는 제피리 회의 런던 헬스케어 컨퍼런스에 참여한다고 발표했습니다. CEO이자 의장인 Samarth Kulkarni 박사는 2024년 11월 20일 수요일 오후 4시에 GMT에서 발표를 진행합니다. 발표는 회사 웹사이트의 '이벤트 및 프레젠테이션' 섹션에서 실시간 웹캐스트를 통해 시청할 수 있으며, 이후 14일 동안 다시 볼 수 있습니다. CRISPR Therapeutics는 중병을 위한 혁신적인 유전자 기반 의약품 개발을 전문으로 하고 있습니다.
CRISPR Therapeutics (Nasdaq: CRSP) a annoncé sa participation à la prochaine Jefferies London Healthcare Conference. Le PDG et président Samarth Kulkarni, Ph.D., fera une présentation le mercredi 20 novembre 2024, à 16h00 GMT. La présentation sera accessible via un webinaire en direct sur le site web de l'entreprise dans la section 'Événements et Présentations', avec un replay disponible pendant 14 jours par la suite. CRISPR Therapeutics se spécialise dans le développement de médicaments basés sur les gènes pour des maladies graves.
CRISPR Therapeutics (Nasdaq: CRSP) hat seine Teilnahme an der bevorstehenden Jefferies London Healthcare Conference bekannt gegeben. CEO und Vorstandsvorsitzender Samarth Kulkarni, Ph.D., wird am Mittwoch, den 20. November 2024, um 16:00 Uhr GMT eine Präsentation halten. Die Präsentation wird über einen Live-Webcast auf der Unternehmenswebsite im Bereich 'Veranstaltungen & Präsentationen' zugänglich sein, mit einer Aufzeichnung, die 14 Tage lang verfügbar ist. CRISPR Therapeutics ist auf die Entwicklung transformierender genbasierter Medikamente für schwere Krankheiten spezialisiert.
- None.
- None.
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of CRISPR Therapeutics, will present at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:00 p.m. GMT.
A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.
About CRISPR Therapeutics
Since its inception over a decade ago, CRISPR Therapeutics has transformed from a research-stage company advancing programs in the field of gene editing, to a company that recently celebrated the historic approval of the first-ever CRISPR-based therapy and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases. CRISPR Therapeutics advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY (exagamglogene autotemcel [exa-cel]) was approved in some countries to treat eligible patients with either of those conditions. The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer and Vertex Pharmaceuticals. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California, and business offices in London, United Kingdom. To learn more, visit www.crisprtx.com.
(CRSP-GEN)
Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com
Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com
FAQ
When is CRISPR Therapeutics (CRSP) presenting at the Jefferies London Healthcare Conference?
How long will the CRSP Jefferies Conference presentation webcast be available?
Where can I watch CRISPR Therapeutics' (CRSP) Jefferies Conference presentation?
Who will represent CRISPR Therapeutics (CRSP) at the 2024 Jefferies London Healthcare Conference?
